Home drugs Kymriah (Tisagenlecleucel)

Kymriah (Tisagenlecleucel)

This page contains brief information about tisagenlecleucel and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)     Kymriah
FDA Approved           Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Tisagenlecleucel is approved to treat:

  • B-cell acute lymphoblastic leukemia. It is used in children and adults up to 25 years old whose disease is refractory (does not respond to treatment) or has relapsed two or more times.
  • B-cell non-Hodgkin lymphoma (NHL), including the following types:
    • Diffuse large B-cell lymphoma (DLBCL).
    • DLBCL in patients who had follicular lymphoma.
    • High-grade B-cell lymphoma.

    It is used in adults whose disease has relapsed or has not gotten better after at least two other types of systemic treatment.

Tisagenlecleucel is only available as part of a special program called Kymriah REMS (Risk Evaluation and Mitigation Strategies).

Tisagenlecleucel is also being studied in the treatment of other types of cancer.

More About Tisagenlecleucel

Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.

MedlinePlus Information on Tisagenlecleucel – A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.